Oxidative stress status in humans with metabolic syndrome

Obesity: Epidemiology, Pathophysiology, and Prevention

Volumn , Issue , 2007, Pages 123-137

  Chen, Chung Yen ^a   Blumberg, Jeffrey B ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953749629     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (109)

1. Reaven, G.M., Banting lecture 1988: role of insulin resistance in human disease, Diabetes, 37, 1595, 1988.
2. WHO, Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications, Report of a WHO Consultation, World Health Organization, Geneva, 1999.
3. Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 486, 2001.
4. Grundy, S.M. et al.; National Heart, Lung, and Blood Institute; American Heart Association, Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition, Circulation, 109, 433, 2004.
5. Ford, E.S., The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study, Atherosclerosis, 173, 309, 2004.
6. Ford, E.S., Giles, W.H., and Dietz, W.H., Prevalence of the metabolic syndrome among U.S. adults:findings from the third National Health and Nutrition Examination Survey, JAMA, 287, 356, 2002.
7. Grundy, S.M., Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute, Arterioscler. Thromb. Vasc. Biol., 25, 2243, 2005.
8. Brownlee, M., Biochemistry and molecular cell biology of diabetic complications, Nature, 414, 813, 2001.
9. Turko, I.V., Marcondes, S., and Murad, F., Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase, Am. J. Physiol. Heart Circ. Physiol., 281, H2289, 2001.
10. Maritim, A.C., Sanders, R.A., and Watkins, 3rd, J.B., Diabetes, oxidative stress, and antioxidants: a reviewx, J. Biochem. Mol. Toxicol., 17, 24, 2003.
11. Griffiths, H.R. et al., Biomarkers, Mol. Aspects. Med., 23, 101, 2002.
12. Requena, J.R., Levine, R.L., and Stadtman, E.R., Recent advances in the analysis of oxidized proteins, Amino Acids, 25, 221, 2003.
13. Tarpey, M.M., Wink, D.A., and Grisham, M.B., Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations, Am. J. Physiol. Regul. Integr. Comp. Physiol., 286, R431, 2004.
14. Cadet, J. et al., Oxidative damage to DNA: formation, measurement and biochemical features, Mutat. Res., 531, 5, 2003.
15. Collins, A.R., The comet assay for DNA damage and repair: principles, applications, and limitations, Mol. Biotechnol., 26, 249, 2004.
16. Abuja, P.M. and Albertini, R. Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clin. Chim. Acta., 306, 1, 2001.
17. Montague, C.T. and O’Rahilly, S., The perils of portliness: causes and consequences of visceral adiposity, Diabetes, 49, 883, 2000.
18. Matsuzawa, Y., Funahashi, T., and Nakamura, T., Molecular mechanism of metabolic syndrome X:contribution of adipocyte-derived bioactive substances, Ann. N.Y. Acad. Sci., 892, 146, 1999.
19. Kahn, B.B., and Flier, J.S., Obesity and insulin resistance, J. Clin. Invest., 106, 473, 2000.
20. Fenster, C.P. et al., Obesity, aerobic exercise, and vascular disease: the role of oxidant stress, Obes. Res., 10, 964, 2002.
21. Furukawa, S. et al., Increased oxidative stress in obesity and its impact on metabolic syndrome, J. Clin. Invest., 114, 1752, 2004.
22. Keaney, Jr., J.F. et al., Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study, Arterioscler. Thromb. Vasc. Biol., 23, 434, 2003.
23. Urakawa, H. et al., Oxidative stress is associated with adiposity and insulin resistance in men, J. Clin. Endocrinol. Metab., 88, 4673, 2003.
24. Couillard, C. et al., Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity, J. Clin. Endocrinol. Metab., 90, 6454, 2005.
25. Visentin, V. et al., Alteration of amine oxidase activity in the adipose tissue of obese subjects, Obes. Res., 12, 547, 2004.
26. Davi, G. et al., Platelet activation in obese women: role of inflammation and oxidant stress, JAMA, 288, 2008, 2002.
27. Turko, I.V., Marcondes, S. and Murad, F. Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. Am. J. Physiol. Heart Circ. Physiol., 281, H2289, 2001.
28. Johansen, J.S. et al., Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice, Cardiovasc. Diabetol., 4, 5, 2005.
29. Koska, J. et al., Insulin, catecholamines, glucose and antioxidant enzymes in oxidative damage during different loads in healthy humans, Physiol. Res., 49(Suppl. 1), S95, 2000.
30. Facchini, F.S. et al., Relation between insulin resistance and plasma concentrations of lipid hydroperoxides, carotenoids, and tocopherols, Am. J. Clin. Nutr., 72, 776, 2000.
31. Koska, J. et al., Malondialdehyde, lipofuscin and activity of antioxidant enzymes during physical exercise in patients with essential hypertension, J. Hypertens., 17, 529, 1999.
32. Konukoglu, D. et al., Plasma homocysteine levels in obese and non-obese subjects with or without hypertension; its relationship with oxidative stress and copper, Clin. Biochem., 36, 405, 2003.
33. Stojiljkovic, M.P. et al., Increasing plasma fatty acids elevates F2-isoprostanes in humans: implications for the cardiovascular risk factor cluster, J. Hypertens., 20, 1215, 2002.
34. Hansel, B. et al., Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity, J. Clin. Endocrinol. Metab., 89, 4963, 2004.
35. Sjogren, P. et al., Measures of oxidized low-density lipoprotein and oxidative stress are not related and not elevated in otherwise healthy men with the metabolic syndrome, Arterioscler. Thromb. Vasc. Biol., 25, 2580, 2005.
36. Witztum, J.L., The oxidation hypothesis of atherosclerosis, Lancet, 344, 793, 1994.
37. Myara, I. et al., Lipoprotein oxidation and plasma vitamin E in nondiabetic normotensive obese patients, Obes. Res., 11, 112, 2003.
38. Kopprasch, S. et al., In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance, Diabetes, 51, 3102, 2002.
39. Mizuno, T. et al., Insulin resistance increases circulating malondialdehyde-modified LDL and impairs endothelial function in healthy young men, Int. J. Cardiol., 97, 455, 2004.
40. Schwenke, D.C. et al., Insulin resistance atherosclerosis study - differences in LDL oxidizability by glycemic status: the insulin resistance atherosclerosis study, Diabetes Care, 26, 1449, 2003.
41. Holvoet, P. et al., The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort, Diabetes, 53, 1068, 2004.
42. Fagerberg, B., Bokemark, L., and Hulthe, J., The metabolic syndrome, smoking, and antibodies to oxidized LDL in 58-year-old clinically healthy men, Nutr. Metab. Cardiovasc. Dis., 11, 227, 2001.
43. Sigurdardottir, V., Fagerberg, B., and Hulthe, J., Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-yearold men (AIR study), J. Intern. Med., 252, 440, 2002.
44. Beckman, J.S. and Koppenol, W.H., Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly, Am. J. Physiol., 271, C1424, 1996.
45. Ceriello, A. et al., Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress, Diabetologia, 44, 834, 2001.
46. Ceriello, A. et al., Role of hyperglycemia in nitrotyrosine postprandial generation, Diabetes Care, 25, 1439, 2002.
47. Marfella, R. et al., Acute hyperglycemia induces an oxidative stress in healthy subjects, J. Clin. Invest., 108, 635, 2001.
48. Bo, S. et al., Relationships between human serum resistin, inflammatory markers and insulin resistance, Int. J. Obes. (Lond.), 29, 1315, 2005.
49. Menke, T. et al., Comparison of coenzyme Q10 plasma levels in obese and normal weight children, Clin. Chim. Acta, 349, 121, 2004.
50. Shin, M.J. and Park, E., Contribution of insulin resistance to reduced antioxidant enzymes and vitamins in nonobese Korean children, Clin. Chim. Acta, 365(1-2), 200, 2006.
51. Konukoglu, D. et al., The erythrocyte glutathione levels during oral glucose tolerance test, J. Endocrinol. Invest., 20, 471, 1997.
52. Ma, S.W., Tomlinson, B., and Benzie, I.F., A study of the effect of oral glucose loading on plasma oxidant:antioxidant balance in normal subjects, Eur. J. Nutr., 44, 250, 2005.
53. Ford, E.S. et al., The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey, Diabetes, 52, 2346, 2003.
54. Csabi, G. et al., Presence of metabolic cardiovascular syndrome in obese children, Eur. J. Pediatr., 159, 91, 2000.
55. Molnar, D., Decsi, T., and Koletzko, B., Reduced antioxidant status in obese children with multimetabolic syndrome, Int. J. Obes. Relat. Metab. Disord., 28, 1197, 2004.
56. Miles, M.V. et al., Coenzyme Q10 changes are associated with metabolic syndrome, Clin. Chim. Acta, 344, 173, 2004.
57. Ozata, M. et al., Increased oxidative stress and hypozincemia in male obesity, Clin. Biochem., 35, 627, 2002.
58. Ji, L.L., Exercise-induced modulation of antioxidant defense, Ann. N.Y. Acad. Sci., 959, 82, 2002.
59. Pedro-Botet, J. et al., Decreased endogenous antioxidant enzymatic status in essential hypertension, J. Hum. Hypertens., 14, 343, 2000.
60. Durrington, P.N., Mackness, B., and Mackness, M.I., Paraoxonase and atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 21, 473, 2001.
61. Watson, A.D. et al., Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein, J. Clin. Invest., 96, 2882, 1995.
62. Ferretti, G. et al., Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females, J. Clin. Endocrinol. Metab., 90, 1728, 2005.
63. Garin, M.C. et al., Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome, J. Clin. Endocrinol. Metab., 90, 2264, 2005.
64. Boemi, M. et al., Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives: influence on the ability of HDL to protect LDL from oxidation, Atherosclerosis, 155, 229, 2001.
65. Senti, M. et al., Antioxidant paraoxonase 1 activity in the metabolic syndrome, J. Clin. Endocrinol. Metab., 88, 5422, 2003.
66. Grundy, S.M. et al.; American Heart Association; National Heart, Lung, and Blood Institute, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation, 112, 2735, 2005.
67. Franklin, B.A. et al., A cardioprotective ‘polypill’? Independent and additive benefits of lifestyle modification, Am. J. Cardiol., 94, 162, 2004.
68. Dumortier, M. et al., Low intensity endurance exercise targeted for lipid oxidation improves body composition and insulin sensitivity in patients with the metabolic syndrome, Diabetes Metab., 29, 509, 2003.
69. Petrella, R.J., Can adoption of regular exercise later in life prevent metabolic risk for cardiovascular disease?, Diabetes Care, 28, 694, 2005.
70. Ekelund, U. et al., Physical activity energy expenditure predicts progression toward the metabolic syndrome independently of aerobic fitness in middle-aged healthy Caucasians: the Medical Research Council Ely Study, Diabetes Care, 28, 1195, 2005.
71. Stewart, K.J. et al., Exercise and risk factors associated with metabolic syndrome in older adults, Am. J. Prev. Med., 28, 9, 2005.
72. American College of Sports Medicine, Position stand: physical activity, physical fitness, and hypertension, Med. Sci. Sports Exerc., 25, I, 1993.
73. Vasankari, T.J. et al., Reduced oxidized LDL levels after a 10-month exercise program, Med. Sci. Sports Exerc., 30, 1496, 1998.
74. Roberts, C.K., Vaziri, N.D., and Barnard, R.J., Effect of diet and exercise intervention on blood pressure, insulin, oxidative stress, and nitric oxide availability, Circulation, 106, 2530, 2002.
75. Roberts, C.K. et al., Effect of a diet and exercise intervention on oxidative stress, inflammation, MMP-9 and monocyte chemotactic activity in men with metabolic syndrome factors, J. Appl. Physiol., 100, 1657, 2006.
76. Dandona, P. et al., The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation, J. Clin. Endocrinol. Metab., 86, 355, 2001.
77. Hsieh, C.J., Orlistat for obesity: benefits beyond weight loss, Diabetes Res. Clin. Pract., 67, 78, 2005.
78. Yesilbursa, D. et al., Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels, Int. J. Obes. (Lond.), 29, 142, 2005.
79. Samuelsson, L., Gottsater, A., and Lindgarde, F., Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors, Diabetes Obes. Metab., 5, 195, 2003.
80. Ozcelik, O. et al., Exercise training as an adjunct to orlistat therapy reduces oxidative stress in obese subjects, Tohoku J. Exp. Med., 206, 313, 2005.
81. Xiang, A.H. et al., Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes, J. Clin. Endocrinol. Metab., 90, 1986, 2005.
82. Tankova, T. et al., The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients, Diabetes Res. Clin. Pract., 59, 43, 2003.
83. Tack, C.J. et al., Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects, Diabetes Care, 21, 796, 1998.
84. Staffileno, B.A., Treating hypertension with cardioprotective therapies: the role of ACE inhibitors, ARBs, and beta-blockers, J. Cardiovasc. Nurs., 20, 354, 2005.
85. Saez, G.T. et al., Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension, Am. J. Hypertens., 17, 809, 2004.
86. Muda, P. et al., Effect of antihypertensive treatment with candesartan or amlodipine on glutathione and its redox status, homocysteine and vitamin concentrations in patients with essential hypertension, J. Hypertens., 23, 105, 2005.
87. Nashar, K. et al., Angiotensin receptor blockade improves arterial distensibility and reduces exerciseinduced pressor responses in obese hypertensive patients with the metabolic syndrome, Am. J. Hypertens., 17, 477, 2004.
88. Sola, S. et al., Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study, Circulation, 111, 343, 2005.
89. Wollin, S.D. and Jones, P.J., Alpha-lipoic acid and cardiovascular disease, J. Nutr., 133, 3327, 2003.
90. Ballantyne, C.M. et al., Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S, Circulation, 104, 3046, 2001.
91. Deedwania, P.C. et al.; STELLAR Study Group, Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome, Am. J. Cardiol., 95, 360, 2005.
92. Oranje, W.A. et al., Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients, Clin. Chim. Acta, 311, 91, 2001.
93. ter Avest, E. et al., Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia, Eur. J. Clin. Invest., 35, 558, 2005.
94. Kural, B.V. et al., The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia, Coronary Artery Dis., 15, 277, 2004.
95. Palomaki, A., Malminiemi, K., and Metsa-Ketela, T., Enhanced oxidizability of ubiquinol and alphatocopherol during lovastatin treatment, FEBS Lett., 410, 254, 1997.
96. Mabuchi, H. et al., Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients, J. Atheroscler. Thromb., 12, 111, 2005.
97. Manuel-Keenoy, B. et al., Impact of vitamin E supplementation on lipoprotein peroxidation and composition in type 1 diabetic patients treated with atorvastatin, Atherosclerosis, 175, 369, 2004.
98. Zhang, B. et al., A comparative crossover study of the effects of fluvastatin and pravastatin (FP-COS) on circulating autoantibodies to oxidized LDL in patients with hypercholesterolemia, J. Atheroscler. Thromb., 12, 41, 2005.
99. Thallinger, C. et al., The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients, Int. J. Clin. Pharmacol. Ther., 43, 551, 2005.
100. Shishehbor, M.H. et al., Statins promote potent systemic antioxidant effects through specific inflammatory pathways, Circulation, 108, 426, 2003.
101. Hajjar, I.M. et al., A randomized, double-blind, controlled trial of vitamin C in the management of hypertension and lipids, Am. J. Ther., 9, 289, 2002.
102. Ward, N.C. et al., The combination of vitamin C and grape-seed polyphenols increases blood pressure:a randomized, double-blind, placebo-controlled trial, J. Hypertens., 23, 427, 2005.
103. Brockes, C. et al., Vitamin E prevents extensive lipid peroxidation in patients with hypertension, Br. J. Biomed. Sci., 60, 5, 2003.
104. Azzi, A. et al., Non-antioxidant molecular functions of alpha-tocopherol (vitamin E), FEBS Lett., 519, 8, 2002.
105. Barbagallo, M. et al., Effects of vitamin E and glutathione on glucose metabolism: role of magnesium, Hypertension, 34, 1002, 1999.
106. Manning, P.J. et al., Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects, Diabetes Care, 27, 2166, 2004.
107. McSorley, P.T. et al., Endothelial function, insulin action and cardiovascular risk factors in young healthy adult offspring of parents with type 2 diabetes: effect of vitamin E in a randomized doubleblind, controlled clinical trial, Diabet. Med., 22, 703, 2005.
108. Skrha, J. et al., Insulin action and fibrinolysis influenced by vitamin E in obese type 2 diabetes mellitus, Diabetes Res. Clin. Pract., 44, 27, 1999.
109. Hildebrandt, W. et al., Effect of thiol antioxidant on body fat and insulin reactivity, J. Mol. Med., 82, 336, 2004.